<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2274">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131555</url>
  </required_header>
  <id_info>
    <org_study_id>AET</org_study_id>
    <nct_id>NCT05131555</nct_id>
  </id_info>
  <brief_title>Influence of Endurance Exercise and Histamine Receptors on the Gene Expression in Skeletal Muscle</brief_title>
  <official_title>Influence of Endurance Training and Histamine Receptor Antagonists on the Transcriptome Response in Human Muscle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research Foundation Flanders</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Blocking histamine H1/H2 receptors blunts chronic endurance training adaptations. The current&#xD;
      study addresses a twofold research question: &quot;What is the influence of endurance training (1)&#xD;
      and histamine H1 and H2 signaling (2) on the gene expression in human skeletal muscle.&quot;&#xD;
      Results from this study will yield more insights into the molecular mechanisms of adaptations&#xD;
      to exercise training.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized double-blinded placebo-controlled cross-over interventional study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in muscle transcriptome (direct response)</measure>
    <time_frame>On each test-day: 0 minutes after the exercise training versus at rest.</time_frame>
    <description>RNA-sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in muscle transcriptome (delayed response)</measure>
    <time_frame>On each test-day: 180 minutes after the exercise training versus at rest.</time_frame>
    <description>RNA-sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle glycogen depletion</measure>
    <time_frame>On each test-day: 0 minutes after the exercise training versus at rest.</time_frame>
    <description>Fluorometric determination of muscle glycogen levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle glycogen resynthesis</measure>
    <time_frame>On each test-day: 180 minutes after the exercise training versus at rest.</time_frame>
    <description>Fluorometric determination of muscle glycogen levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma volume change</measure>
    <time_frame>Change from rest to different time-points after exercise (0, 30, 60, 120 and 180 minutes after the exercise training).</time_frame>
    <description>Plasma volume based on hemoglobin and hematocrit concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate during the exercise training</measure>
    <time_frame>Continuously during training on each test-day.</time_frame>
    <description>Heart rate during the exercise training.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lactate</measure>
    <time_frame>On each test-day at 10 time-points: at rest, during exercise and 0, 30, 60, 120 and 180 minutes after the exercise training.</time_frame>
    <description>Capillary lactate concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose</measure>
    <time_frame>On each test-day at 10 time-points: at rest, during exercise and 0, 30, 60, 120 and 180 minutes after the exercise training.</time_frame>
    <description>Capillary glucose concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood histamine</measure>
    <time_frame>On each test-day at 6 time-points: at rest and 0, 30, 60, 120 and 180 minutes after the exercise training.</time_frame>
    <description>histamine concentration in blood samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood insulin</measure>
    <time_frame>On each test-day at 6 time-points: at rest and 0, 30, 60, 120 and 180 minutes after the exercise training.</time_frame>
    <description>insulin concentration in blood samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle signaling pathways relevant for glucose metabolism and cardiovascular health</measure>
    <time_frame>On each test-day: at rest, 0 minutes and 180 minutes after the exercise training.</time_frame>
    <description>Phosphorylation status of proteins assessed by Western Blotting</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Exercise</condition>
  <condition>Histamine</condition>
  <arm_group>
    <arm_group_label>1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>lactose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H1 blockade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>540 mg Fexofenadine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H2 blockade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg Famotidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo: Placebo + exercise training.</intervention_name>
    <description>Oral placebo Exercise training: Interval-based cycling exercise</description>
    <arm_group_label>1: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H1 blockade: H1 receptor antagonist + exercise training</intervention_name>
    <description>H1 blockade: oral blockade Exercise training: Interval-based cycling exercise</description>
    <arm_group_label>H1 blockade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H2 Blockade: H2 receptor antagonist + exercise training</intervention_name>
    <description>H2 blockade: oral blockade Exercise training: Interval-based cycling exercise</description>
    <arm_group_label>H2 blockade</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female&#xD;
&#xD;
          -  18-45 years&#xD;
&#xD;
          -  not to medium physically active&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Chronic disease&#xD;
&#xD;
          -  Supplement or medication intake&#xD;
&#xD;
          -  Seasonal allergies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim Derave, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wim Derave, Professor</last_name>
    <phone>92646326</phone>
    <phone_ext>+32</phone_ext>
    <email>wim.derave@ugent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of movement and sports sciences, Ghent University, Belgium</name>
      <address>
        <city>Ghent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wim Derave, Professor</last_name>
      <phone>92646326</phone>
      <phone_ext>+32</phone_ext>
      <email>wim.derave@ugent.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Ghent</investigator_affiliation>
    <investigator_full_name>Wim Derave</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histamine H2 Antagonists</mesh_term>
    <mesh_term>Histamine H1 Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

